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■ Abstract 
OBJECTIVES: Oxidative stress can contribute to microvas-
cular complications in diabetes. A decisive event associated 
with this condition may be the decrease in the synthesis of 
zinc-containing antioxidant enzymes such as superoxide 
dismutase and glutathione peroxidase. This consideration 
led us to investigate the effect of zinc supplementation ver-
sus placebo on microalbuminuria in diabetic patients in a 
randomized double blind clinical trial. METHODS: Fifty 
diabetic patients with microalbuminuria were enrolled. Fast-
ing plasma glucose, HbA1c, lipid profiles, plasma zinc levels 
and random urine for albumin and creatinine were meas-
ured. Patients randomly received 30 mg elemental zinc 
(group 1) or placebo (group 2) for 3 months. After a 4 week 
wash-out period, the groups were crossed over (i.e. the zinc 
group were given placebo, and the placebo group were given 
zinc) and the protocol was repeated. RESULTS: From an 
initial number of 50 selected patients (25 in each of two 
groups), 39 patients (21 in group 1 and 18 in group 2) com-
pleted the study. In group 1, after zinc supplementation, 
urinary albumin excretion decreased significantly from 86.5 
± 57 to 75 ± 71 mg/g (p = 0.01). After placebo, patients in 
group 1 showed no significant reduction in microalbuminu-
ria (85 ± 72 mg/g to 83 ± 63 mg/g creatinine). In group 2, 
no change in albumin excretion was observed after placebo 
treatment (90.5 ± 63 mg/g to 90 ± 60 mg/g creatinine). Af-
ter zinc supplementation, a significant reduction was ob-
served in albumin excretion, from 90 ± 60 mg/g to 85 ± 57 
mg/g creatinine (p = 0.003). CONCLUSIONS: Zinc sup-
plementation reduced albumin excretion in microalbuminu-
ric type 2 diabetic patients. This outcome may be due to the 
antioxidant effect of zinc. 
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Introduction 
 
         enal failure is the most important complication 
     arising from diabetes [1]. It is a major cause of 
     mortality and morbidity in diabetic patients [1, 
2]. Microalbumiuria is an early indicator of renal im-
pairment. It is important to identify diabetic patients 
with this early stage of renal failure in order to set 
them on medication or diet. In a Japanese population 
the prevalence of microalbumiuria among type 2 dia-
betic patients was recently reported to be 31.6% [3]. In 
an Iranian population, the average incidence rate 
among type 2 diabetic patients was 82.3/1000 per-
son/year, with a significantly higher incidence for men 
than for women (104.4 vs. 66.2/1000 person/year, p < 
0.001) [4]. 
There is particular interest in the idea that oxidative 
stress is relevant in the pathogenesis of diabetic neph-
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ropathy. Oxidative stress can be caused either by the 
increased production of reactive oxygen species (ROS) 
or a deficiency in antioxidant defenses [5]. Antioxidant 
deficiency can result from low intake of vitamins, such 
as vitamins C and E, or impaired synthesis of enzymes, 
such as superoxide dismutase and glutathione peroxi-
dase, due to zinc deficiency. Zinc is a part of these en-
zymes’ structures and its deficiency may impair their 
synthesis [5]. Another hypothesis is that hyperglycemia 
causes endothelial cell dysfunction through a number 
of pathways, including increased oxidative stress [6, 7] 
and impaired endothelium-derived relaxing factors 
such as nitric oxide [8, 9]. In comparison with non-
diabetic individuals, diabetic patients have an inferior 
antioxidant status [5]. Also, diabetes is accompanied by 
hyperzincuria [10]. The combination of these mecha-
nisms can increase oxidative stress. 
Given these considerations, it seems reasonable 
that antioxidants, such as zinc, might be used to treat 
or prevent diabetic nephropathy. Unfortunately, there 
are few studies in this field, which contain some con-
troversial results. In one trial, using a combination of 
zinc and magnesium, a decreased urinary albumin ex-
cretion was observed without any significant effect on 
blood pressure or lipid profiles [11]. Another study 
found that intake of zinc and melatonin for three 
months reduced plasma lipid concentrations and uri-
nary albumin excretion [12]. In yet another trial, re-
duced HbA1c levels were detected after zinc supple-
mentation [13], whilst elsewhere it was found that 
HbA1c and lipid profiles remained unchanged after 
three months of zinc supplementation [14]. 
Due to these divergent results, further studies are 
needed to determine more accurately the effect of zinc 
supplementation on the development of renal disease. 
This led us to design a randomized placebo-controlled 
clinical trial to investigate the role of the zinc supple-
mentation versus placebo on microalbuminuria. 
Subjects and methods 
Subjects 
A single-center double blind randomized placebo-
controlled crossover clinical trial was performed in Is-
fahan Endocrine and Metabolic Research Center 
(IEMRC) between September 2007 and May 2008. All 
patients were involved in the study for 7 months. Fifty 
nine type 2 diabetic patients with microalbuminuria (30 
mg/g ≤ albumin/creatinine < 300 mg/g) were en-
rolled by consecutive patient selection. Each patient 
had microalbuminuria documented in at least two 
urine samples within six months. 
All patients were receiving angiotensin converting 
enzyme (ACE) inhibitors or angiotensin (AT) receptor 
blockers for albuminuria. We added zinc to their medi-
cation. Demographic data and medication taking were 
recorded. Afterwards, patients were examined and 
blood pressure (BP) was measured. Patients were sit-
ting at least for five minutes before measurement of 
BP [15]. BP was measured twice at ten-minute inter-
vals, before taking any probable antihypertensive 
medication [15]. It was measured in both arms using 
mercury sphygmomanometer (Yamasu, Japan); if we 
observed a disparity in measurement, the higher value 
was recorded [16]. 
The day after the first visit, early morning fasting 
blood and urinary samples were obtained to measure 
random urine for urinalysis, albumin and creatinine. At 
the same incidence we measured fasting plasma glu-
cose, serum creatinine, HbA1c, lipid profiles (including 
total cholesterol, triglyceride, HDL and LDL choles-
terol), plasma zinc levels. Also, we did liver function 
test by measuring serum aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT). 
Nine patients were excluded after the initial visit 
because they did not meet the eligibility criteria, yield-
ing a total of 50 patients available for the study. Inclu-
sion and exclusion criteria for the study are shown in 
Table 1. 
 
 
 
Table 1. Inclusion and exclusion criteria to investigate the effect of 
zinc versus placebo on microalbuminuria in type 2 diabetic patients 
 
 
 Inclusion criteria 
- Proven microalbuminuria based on at least two urine samples  
  within six months, despite standard treatment including, ACE- 
  inhibitors or AT-receptor blockers 
 
 -Serum creatinine level in normal range 
 
 
Exclusion criteria 
 
- Multivitamin supplementation within the month before begin- 
  ning the study 
- Pregnancy or planned pregnancy 
- Heart failure based on clinical examination 
 
- Urinary tract infection 
 
- Elevated concentration of liver enzymes (more than two fold  
   above normal) 
- Need for changing medication 
 
- Poor compliance due to: 1. irregular medication intake based on 
  capsule counts, 2. lack of regular visits to the clinic, 3. wish to  
  discontinue the study 
 
 -  Drug complications 
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A simple method was used to randomize the study 
patients. 25 cards were marked ‘zinc’, and another 25 
cards were marked ‘placebo’. The cards were shuffled 
to remove any semblance of order and were placed in 
a box. After enrollment ,each patient was asked to take 
a card out of the box, under the supervision of an 
IEMRC staff member. An independent person from 
IEMRC was given sole responsibility for determining 
which patients should receive placebo and which 
should receive zinc in the first phase of the study. All 
medications (zinc or placebo) rested in the hands of 
this person. The randomized patient distribution was 
not disclosed to the research team or to the patients at 
any time during the study. The codes were destroyed at 
the end of the study. 
In this way, half of the patients (group 1) received 
30 mg elemental zinc, and the other half (group 2) re-
ceived the placebo, each day for 3 months. The zinc 
sulfate was encapsulated in an oval yellow capsule (Al-
havi, Iran). Each capsule contained 132 mg zinc sul-
fate, amounting to 30 mg elemental zinc. The placebo 
capsules contained 30 mg of lactose and were made to 
appear the same as the zinc capsules, in size, shape and 
color. The prescribed zinc dosage was based on the 
method used in other studies [11, 14]. 
Forty five days after treatment (zinc or placebo), 
patients were visited and interviewed about possible 
side effects, and to determine the degree of compli-
ance. After 3 months of treatment, at the end of the 
first phase of the study, all of the laboratory tests and 
clinical evaluations were repeated as per the initial visit. 
The study protocol is shown in Figure 1. 
After a 4-week wash-out period, the groups were 
crossed over, so that patients (group 1) initially receiv-
ing zinc received the placebo, and patients previously 
taking the placebo (group 2) now received 30 mg zinc 
per day. The protocol was repeated again for 3 
months. Patient compliance was assessed by capsule 
counts at each visit, and through measurement of 
changes in zinc serum levels. 
A total of eight patients stopped taking part in the 
first phase of the study. Two withdrew due to epigas-
tric pain (one patient in each group). Two patients 
needed a change of drugs (one group 1 patient was put 
on statins, and one group 2 patient was put on gemfi-
brozil). Two other patients started with insulin. Fur-
thermore, two group 1 patients were withdrawn for 
poor compliance. 
At the beginning of the second phase of the study, 
three of the group 1 patients refused to start the sec-
ond phase. However, as they had completed the first 
phase, in which they were all taking zinc, we have in-
cluded their data in the first phase analysis. In total, 39 
patients completed both phases of the study. The re-
sults and statistics were presented as intentions for 
treatment. 
The IEMRC Medical Ethics Committee approved 
the study protocol, and all patients gave their written 
consent. The study complied with the current version 
of the Declaration of Helsinki. 
Laboratory assessments 
After 12 hours of 
overnight fasting, be-
tween 8 and 10 a.m., be-
fore taking medications, 
blood and urine samples 
were collected from all 
patients. The samples 
were stored at -70°C at 
the IEMRC laboratory 
and assayed at the end of 
the study. 
Urinary albumin con-
centrations were meas-
ured by immunoturbidi-
metric assay (Pars Az-
mun kit). Its intra- and 
inter-assay CV was 1.3% 
and 2.9%, respectively, 
and was reported in 
mg/dl. Urine and serum 
 
 
 
3 months 3 months4 weeks
Wash out
period
Group 1 (zinc, n = 21)
Group 2 (placebo, n = 21)
Group 2 (zinc, n = 21)
Group 1 (placebo, n = 18)
Zn = 76 ± 16
UAE = 86.5 ± 57
Zn = 93 ± 20*
UAE = 75 ± 71*
Zn = 73 ± 16
UAE = 90.5 ± 63
Zn = 75 ± 14
UAE = 90 ± 60
Zn = 75.5 ± 11
UAE = 90 ± 60
Zn = 95 ± 22*
UAE = 78 ± 57*
Zn = 75 ± 16
UAE = 85 ± 72
Zn = 75 ± 15
UAE = 83 ± 63
 
 
Figure 1. Schematic of the study protocol and outcome data. Comparison of uri-
nary albumin excretion and serum zinc levels in type 2 diabetic patients before and af-
ter treatment with placebo and zinc in group 1 and group 2 (separately). Group 1 re-
ceived zinc in the first and placebo in the second phase, group 2 received placebo in 
the first and zinc in the second phase. Data are mean ± SD at 4 reading points: base-
line, after 3 months of treatment, after wash out and after additional 3 months of treat-
ment. Zn: serum zinc level (µg/dl). UAE: urinary albumin excretion (mg/g). * p < 0.05.  
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creatinine was measured using Jaffe reaction [17]. Its 
intra assay CV was 3.2% and urine results were ex-
pressed in g/dl excretion. Microalbuminuria was de-
termined by calculating the ratio of urine albumin to 
urine creatinine and was expressed in mg/g [18]. The 
glomerular filtration rate (GFR) was measured using 
the Cockcroft-Gault equation by calculating (140-age) 
× (weight in kg)]/(72 × serum creatinine in mg/dl) in 
males, and factored by 0.85 for females [19]. Serum 
AST and ALT levels were measured by the IFCC 
method, its intra and inter assay CV was 2.8% and 
1.5%, respectively. Normal value for both levels was 
less than 41 IU/l. 
Fasting plasma glucose was measured by the enzy-
matic method. Its intra- and inter-assay CV was 1.5% 
and 0.91%, respectively. Serum triglyceride, total cho-
lesterol and HDL were enzymatically measured. Intra- 
and inter-assay CV for triglyceride was 1.5% and 1.2%, 
respectively. Intra- and inter-assay CV for HDL was 
1.8% and 1.3%, respectively. The values 
for total cholesterol were 0.95% and 
1.1%, respectively. The plasma LDL 
cholesterol concentration was then cal-
culated by the Friedewald formula [20]: 
LDL cholesterol = total cholesterol - 
HDL - VLDL (triglycerides/5) if 
triglyceride is <400 mg /dl. All bio-
chemical assays were measured by Pars 
Azmun kits, and BT 300 plus automatic 
analyzer. 
HbA1 was measured by chroma-
tographic method using commercial kit 
(BioSystem S.A). Its intra- and inter-
assay CV was 5.8% and 6.7%. Plasma 
zinc level was determined by flame 
atomic absorption spectrometry (spectr 
AA 220) [21]. 
Statistical analysis 
The power of the study was 80% based on a previ-
ously published study [11]. Kolmogorov-Smirnov test 
was performed to assess the normality of the variables 
before further statistical analysis. All data in this study 
are normally distributed, and are presented as mean ± 
SD. 
Zinc or placebo effects for variables in the same 
individuals were analyzed by paired t test. Data be-
tween the two groups were compared using student’s t 
test. Chi-square test was used to compare qualitative 
variables between the two groups. Multiple regression 
analysis was used to adjust for the effect of HbA1c on 
albuminuria. p-values less than 0.05 were considered 
statistically significant. Statistical analysis was per-
formed by Statistics Package for Social Science (SPSS 
version 13.0, SPSS Inc., Chicago, IL, USA). 
Results 
Out of 50 patients selected at the beginning of the 
study, forty two (84%) completed the first phase. Co-
incidentally, four patients in each group had withdrawn 
at the end of the first phase, leaving 21 patients in each 
group. By the end of the second phase there were 39 
(78%) patients remaining i.e. 21 in group 1, and 18 in 
group 2. As shown in Table 2, at the beginning of the 
study, basal characteristics were not significantly dif-
ferent between two groups. 
Statistical analysis at the beginning of the study 
showed that both groups were biochemically and clini-
cally similar, with the exception of serum triglyceride. 
In particular, urinary albumin excretion was not statis-
tically different between both groups (Table 3). 
Zinc levels and urinary albumin excretion were 
compared at baseline and after wash-out period in 
both groups. The wash-out was carried out for 4 weeks 
to make sure that it was long enough to eliminate the 
effects of zinc and placebo before starting the second 
phase of the study. The results showed that there was 
no difference between basal parameters at the begin-
ning of first and second phases of the study. 
In group 1 (patients who received zinc in the first 
phase and placebo in the second phase), zinc levels 
were 76 ± 16 µg/dl at baseline and 75 ± 16 µg/dl at 
post wash-out period (p = 0.4). Urinary albumin excre-
tion in this group was 86.5 ± 62 mg/g at baseline and 
85 ± 72 mg/g at post wash-out period (p = 0.2). In 
 
Table 2. Baseline characteristics of the two groups of type 2 diabetic patients 
with microalbuminuria 
 
 
Characteristic 
 
   Group 1 
   (n = 21) 
 
  Group 2 
  (n = 21) 
 
p 
 
Age (yr) 52.
 
0 
 
± 9.
 
3 54.
 
5 
 
± 
 
9.
 
2 
  
n
 
.s. 
 
Male (%) 
 
62 52 
  
n
 
.s. 
 
Duration of diabetes (yr) 12.
 
0 
 
± 6.
 
1 10.
 
5 
 
± 
 
5.
 
7 
  
n
 
.s. 
 
Retinopathy (%) 
 
29 38 
  
n
 
.s. 
 
On insulin (%) 
 
50 47 
  
n
 
.s. 
 
On oral antidiabetic drugs (%)
 
67 50 
  
n
 
.s. 
 
Smoker (%) 
 
  0   5 
  
n
 
.s. 
 
Aspirin (%) 
 
76 76 
  
n
 
.s. 
 
Legend: Data are mean ± SD or percent. n.s.: not significant. 
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group 2 (patients who received placebo in first phase 
and zinc in second phase), zinc levels were 73 ± 16 
µg/dl and 75.5 ± 11 µg/dl at baseline and post wash-
out period, respectively (p = 0.4). Urinary albumin ex-
cretion in this group was 90.5 ± 63 mg/g and 90 ± 60 
mg/g at baseline and post wash-out period, respec-
tively (p = 0.9; Figure 1). 
At baseline, 4 patients in group 1 and 4 in group 2 
had low concentrations of serum zinc. Zinc was con-
sidered to be deficient when serum zinc level was <60 
µg/dl [22]. GFR was not altered during zinc supple-
mentation or placebo compared with baseline (Tables 
4 and 5). 
Effects on serum zinc level and microalbu-
minuria 
Compared with baseline (p = 0.001 
in both groups), serum zinc levels in-
creased significantly in both groups 
after zinc supplementation.. As ex-
pected, no significant changes in zinc 
levels were observed after placebo 
administration (p = 0.6 for group 1, 
and p = 0.2 for group 2; Figure 1). 
In comparison with baseline after 3 
months of zinc supplementation, uri-
nary albumin excretion decreased sig-
nificantly (p = 0.01 in group 1 and p 
= 0.003 in group 2; Figures 1 and 2). 
After 3 months of placebo intake, 
there were no significant changes in 
urinary albumin excretion compared 
with baselines in both groups (Figures 
1 and 2). 
We also compared the two groups at the end of the 
first and at the end of the second phase. In the first 
phase, where patients in groups 1 received zinc and in 
group 2 placebo, differences in plasma zinc levels and 
urinary albumin excretion between both groups were 
statistically significant (zinc: 93 ± 20 µg/dl vs. 75 ± 14 
µg/dl; urinary albumin excretion: 75 ± 71 mg/g vs. 90 
± 60 mg/g; p < 0.05). This confirms the positive effect 
of zinc. In the second-phase of the study, when pa-
tients in the groups switched treatment, only plasma 
zinc level but not urinary albumin excretion were sig-
nificantly different between two groups (Table 6).  
Table 3. Baseline biochemical and clinical characteristics of the two groups of 
type 2 diabetic patients with microalbuminuria 
 
 
Characteristic 
 
   Group 1 
   (n = 21) 
 
  Group 2 
  (n = 21) 
 
p 
 
UAE (mg/g) 86.
 
5 
 
± 57.
 
0 90.
 
5
 
±
 
63.
 
0 
  
n
 
.s. 
 
Plasma zinc (µg/dl) 76.
 
0 
 
± 16.
 
0 73.
 
0
 
±
 
16.
 
0 
  
n
 
.s. 
 
FPG (mg/dl) 167.
 
0 
 
± 46.
 
0 163.
 
0
 
±
 
47.
 
0 
  
n
 
.s. 
 
HbA1c (%) 8.
 
0 
 
± 1.
 
4 7.
 
9
 
±
 
1.
 
6 
  
n
 
.s. 
 
SBP (mmHg) 122.
 
0 
 
± 10.
 
0 126.
 
0
 
±
 
14.
 
0 
  
n
 
.s. 
 
DBP (mmHg) 76.
 
5 
 
± 6.
 
0 78.
 
0
 
±
 
8.
 
0 
  
n
 
.s. 
 
Cholesterol (mg/dl) 183.
 
0 
 
± 37.
 
0 195.
 
0
 
±
 
31.
 
0 
  
n
 
.s. 
 
Triglyceride (mg/dl) 159.
 
0 
 
± 77.
 
0 230.
 
0
 
±
 
72.
 
0 
  
0.
 
004 
 
HDL (mg/dl) 45.
 
0 
 
± 12.
 
0 41.
 
0
 
±
 
7.
 
0 
  
n
 
.s. 
 
LDL (mg/dl) 105.
 
0 
 
± 34.
 
0 108.
 
0
 
±
 
27.
 
0 
  
n
 
.s. 
 
Legend: Data are mean ± SD. UAE: urinary albumin excretion. FPG: fasting plasma glu-
cose. SBP: systolic blood pressure. DBP: diastolic blood pressure. HDL: high-density lipo-
protein. LDL: low-density lipoprotein. n.s.: not significant. 
 
 
 
 
 
Table 4. Comparison of blood pressure and biochemical characteristics in type 2 diabetic patients before and after treatment 
with zinc (first phase) and placebo (second phase) in group 1 
 
 
Characteristic 
 
     Zinc (n = 21) 
 
     Before treatment           After treatment 
  
Placebo (n = 18)  
 
 Before treatment          After treatment 
 
FPG (mg/dl) 167.
 
0 
 
± 46.
 
0 160.
 
0 
 
± 
 
61.
 
0 
 
172.
 
0
 
± 
 
68.
 
0 
 
165.
 
0 
 
± 
 
54.
 
0 
 
HbA1c (%) 8.
 
0 
 
± 1.
 
4 7.
 
2 
 
± 
 
1.
 
4* 
 
7.
 
5
 
± 
 
1.
 
5 
 
7.
 
4 
 
± 
 
1.
 
8 
 
GFR (ml/min) 84.
 
0 
 
± 31.
 
0 88.
 
0 
 
± 
 
29.
 
0 
 
85.
 
0
 
± 
 
26.
 
0 
 
88.
 
0 
 
± 
 
24.
 
0 
 
SBP (mmHg) 122.
 
0 
 
± 10.
 
0 119.
 
0 
 
± 
 
9.
 
5 
 
115.
 
0
 
± 
 
26.
 
0 
 
118.
 
0 
 
± 
 
7.
 
0 
 
DBP (mmHg) 76.
 
5 
 
± 6.
 
0 75.
 
5 
 
± 
 
6.
 
1 
 
75.
 
5
 
± 
 
4.
 
6 
 
76.
 
0 
 
± 
 
4.
 
3 
 
Cholesterol (mg/dl) 183.
 
0 
 
± 37.
 
0 175.
 
0 
 
± 
 
28.
 
0 
 
182.
 
0
 
± 
 
31.
 
0 
 
171.
 
0 
 
± 
 
30.
 
0 
 
Triglyceride (mg/dl) 159.
 
0 
 
± 77.
 
0 149.
 
0 
 
± 
 
91.
 
0 
 
156.
 
0
 
± 
 
72.
 
0 
 
158.
 
0 
 
± 
 
81.
 
0 
 
HDL (mg/dl) 45.
 
0 
 
± 12.
 
0 41.
 
0 
 
± 
 
12.
 
0 
 
42.
 
0
 
± 
 
14.
 
0 
 
38.
 
0 
 
± 
 
12.
 
0 
 
LDL (mg/dl) 105.
 
0 
 
± 34.
 
0 109.
 
0 
 
± 
 
26.
 
0 
 
109.
 
0
 
± 
 
31.
 
0 
 
102.
 
0 
 
± 
 
26.
 
0 
 
Legend: Data are mean ± SD. FPG: fasting plasma glucose. GFR: glomerular filtration rate. SBP: systolic blood pressure. DBP: diastolic blood 
pressure. HDL: high-density lipoprotein. LDL: low-density lipoprotein. * p < 0.05. 
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Effects on fasting plasma glucose and HbA1c 
Fasting plasma glucose levels were not altered after 
3 months of zinc supplementation or placebo intake in 
either group (Tables 4 and 5). After 3 months of zinc 
supplementation, HbA1c was reduced significantly in 
group 1 and remained unaltered in group 2, when 
compared with baseline over the study period. Analysis 
using general linear model (ANCOVA), showed that 
the effect of zinc on decreasing urine albumin excre-
tion was independent of the change in HbA1c (p = 
0.03). 
Effects on blood pressure 
The mean values of systolic and diastolic blood 
pressure after 3 months of zinc supplementation or 
placebo were not significantly different from baseline 
(Tables 4 and 5). 
Effects on plasma lipids 
After 3 months of zinc supplementation, mean se-
rum levels of total cholesterol, triglyceride, HDL and 
LDL cholesterol, were not changed in either group 
compared with baseline (Tables 3 and 4). Also, when 
they received placebo, no significant changes were ob-
served in the mean values of serum lipid profiles be-
tween the two groups in comparison with baseline 
(Tables 4 and 5). 
Discussion 
The main purpose of this study was to investigate 
the effect of zinc supplementation on microalbuminu-
ria. However, other variables such as hyperglycemia, 
hypertension and hyperlipidemia may affect albumin 
excretion. Therefore, we included these variables in the 
study [11, 23]. Our results showed that zinc supple-
mentation decreases microalbuminuria in type 2 dia-
betic patients. This effect seems to be due to the anti-
oxidant property of zinc. Serum zinc levels increased 
significantly in both groups when compared with base-
line, but this effect was observed only after zinc sup-
plementation. It was not increased after placebo. This 
result was expected, and showed good compliance of 
patients with the treatment. 
Table 5. Comparison of blood pressure and biochemical characteristics in type 2 diabetic patients before and after treatment with 
placebo (first phase) and zinc (second phase) in group 2 
 
 
Characteristic 
 
     Placebo (n = 21) 
 
     Before treatment           After treatment 
  
Zinc (n = 18)  
 
 Before treatment          After treatment 
 
FPG (mg/dl) 163.
 
0 
 
± 47.
 
0 154.
 
0 
 
± 
 
43.
 
0 
 
158.
 
5
 
± 
 
36.
 
0 
 
165.
 
0 
 
± 
 
58.
 
0 
 
HbA1c (%) 7.
 
9 
 
± 1.
 
6 7.
 
5 
 
± 
 
1.
 
8 
 
7.
 
3
 
± 
 
1.
 
6 
 
7.
 
2 
 
± 
 
1.
 
8 
 
GFR (ml/min) 78.
 
0 
 
± 14.
 
0 83.
 
0 
 
± 
 
20.
 
0 
 
81.
 
0
 
± 
 
18.
 
0 
 
85.
 
0 
 
± 
 
20.
 
0 
 
SBP (mmHg) 126.
 
0 
 
± 14.
 
0 125.
 
5 
 
± 
 
14.
 
0 
 
125.
 
0
 
± 
 
12.
 
5 
 
123.
 
0 
 
± 
 
10.
 
0 
 
DBP (mmHg) 78.
 
0 
 
± 8.
 
0 77.
 
0 
 
± 
 
16.
 
0 
 
77.
 
0
 
± 
 
6.
 
0 
 
75.
 
0 
 
± 
 
6.
 
0 
 
Cholesterol (mg/dl) 195.
 
0 
 
± 31.
 
0 180.
 
0 
 
± 
 
32.
 
0 
 
191.
 
0
 
± 
 
33.
 
0 
 
181.
 
0 
 
± 
 
34.
 
0 
 
Triglyceride (mg/dl) 230.
 
0 
 
± 72.
 
0 198.
 
0 
 
± 
 
66.
 
0 
 
216.
 
0
 
± 
 
75.
 
0 
 
193.
 
0 
 
± 
 
59.
 
0 
 
HDL (mg/dl) 41.
 
0 
 
± 7.
 
0 39.
 
0 
 
± 
 
7.
 
0 
 
37.
 
0
 
± 
 
6.
 
0 
 
35.
 
0 
 
± 
 
6.
 
0 
 
LDL (mg/dl) 108.
 
0 
 
± 27.
 
0 102.
 
0 
 
± 
 
22.
 
0 
 
110.
 
0
 
± 
 
26.
 
0 
 
107.
 
0 
 
± 
 
31.
 
0 
 
Legend: Data are mean ± SD. FPG: fasting plasma glucose. GFR: glomerular filtration rate. SBP: systolic blood pressure. DBP: diastolic blood 
pressure. HDL: high-density lipoprotein. LDL: low-density lipoprotein. 
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Figure 2. Comparison of urinary albumin excretion in type 
2 diabetic patients before and after treatment with zinc or 
placebo in group 1 and group 2. Group 1 received zinc in 
the first and placebo in the second phase, group 2 recei-
ved placebo in the first and zinc in the second phase. Rec-
tangle, lower part: 25th percentile. Rectangle, upper part: 
75th percentile. Line below rectangle: smallest value that is 
not an outlier. Line above rectangle: largest value that is 
not an outlier. * p < 0.05. 
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The present study showed that 3 months of zinc 
supplementation significantly reduced urinary albumin 
excretion, a marker for renal function. This finding 
was observed in both groups during zinc supplementa-
tion and it may be due to the antioxidant effect of zinc. 
Our findings are consistent with results of other re-
cently published studies, in which the urinary albumin 
excretion ratio was seen to be decreased in diabetic pa-
tients who had received 30 mg zinc and magnesium 
[11] or zinc and melatonin for 3 months [12]. 
Similar to another study, the mean levels of fasting 
plasma glucose were not significantly changed in either 
group during zinc or placebo intake (Tables 4 and 5) 
[11]. In contrast to some studies [11, 12], but in agree-
ment with at least one other [13], there were no signifi-
cant changes in HbA1c in either group when they re-
ceived placebo. However, we found a reduction in 
HbA1c in one zinc treated group. Zinc supplementa-
tion decreased HbA1c with no effect on fasting plasma 
glucose (Tables 4 and 5). It might have also decreased 
postprandial plasma glucose concentration, which was 
not measured in our study. On the other hand, zinc 
may inhibit oxidation of hemoglobin despite elevated 
blood glucose, due to its antioxidant effect. 
The role of intensive glycemic control on microal-
buminuria in diabetic patients remains controversial. 
However, one study has shown that poor glycemic 
control may be associated with the development of 
overt proteinuria in type 2 diabetic patients with mi-
croalbuminuria [24]. Our analysis using a general linear 
model showed that the effect of zinc on decreasing 
urine albumin excretion was independent of the 
change in HbA1c. Therefore, beneficial effects of zinc 
on microalbuminuria, independent of glycemic control, 
suggests that zinc has a renoprotective effect, puta-
tively via its antioxidant property. It would be useful to 
undertake further study to discover more about the 
mechanism and the effect that zinc has on the function 
of alpha- and beta-cells, and on insulin resistance. 
Blood pressure was not observed to change during 
the study period. As hypertension is a potent risk fac-
tor for microalbuminuria [25], it seems that the reduc-
tion of albumin excretion is independent of changes in 
blood pressure (Tables 4 and 5). 
In accordance to previously published studies [11, 
14], we found no significant changes in serum lipid 
levels. However, in another report, serum lipid concen-
trations decreased after zinc supplementation [12]. In 
patients with type 2 diabetes, hyperlipidemia is a risk 
factor for the progression of nephropathy [26]. There-
fore, our findings suggest that zinc does not decrease 
microalbuminuria through the reduction of lipid pro-
files. 
A limitation of our study may be that we did not 
measure C-reactive protein (CRP) as an inflammatory 
factor, which may affect microalbuminuria. However, 
the correlation between CRP and albuminuria has al-
ready been reported to be low [27]. Zinc may also af-
fect the alpha-cell function. However, it was not the 
main purpose of this study to detect the effect of zinc 
on islet function and glucagon levels. We recommend 
that this mechanism is investigated in future studies. 
Table 6. Comparison of albuminuria, plasma zinc level, blood pressure and biochemical parameters between type 2 diabetic pa-
tients in group 1 and group 2 at the end of each of the two study phases 
 
 
Characteristic 
 
     First phase 
 
     Group 1 (n = 21)        Group 2 (n = 21) 
  
Second phase  
 
 Group 1 (n = 18)        Group 2 (n = 21) 
 
UAE (mg/g) 75.
 
0 
 
± 71.
 
0 90.
 
0 
 
± 
 
60.
 
0* 
 
83.
 
0
 
± 
 
63.
 
0 
 
78.
 
0 
 
± 
 
57.
 
0 
 
Plasma zinc (µg/dl) 93.
 
0 
 
± 20.
 
0 75.
 
0 
 
± 
 
14.
 
0* 
 
75.
 
0
 
± 
 
15.
 
0 
 
95.
 
0 
 
± 
 
22.
 
0* 
 
FPG (mg/dl) 160.
 
0 
 
± 61.
 
0 154.
 
0 
 
± 
 
43.
 
0 
 
165.
 
0
 
± 
 
54.
 
0 
 
165.
 
0 
 
± 
 
58.
 
0 
 
HbA1c (%) 7.
 
2 
 
± 1.
 
4 7.
 
5 
 
± 
 
1.
 
8 
 
7.
 
4
 
± 
 
1.
 
8 
 
7.
 
2 
 
± 
 
1.
 
8 
 
Creatinine clearance (ml/min) 88.
 
0 
 
± 29.
 
0 83.
 
0 
 
± 
 
20.
 
0 
 
88.
 
0
 
± 
 
24.
 
0 
 
85.
 
0 
 
± 
 
20.
 
0 
 
SBP (mmHg) 119.
 
0 
 
± 9.
 
5 125.
 
5 
 
± 
 
14.
 
0 
 
118.
 
0
 
± 
 
7.
 
0 
 
123.
 
0 
 
± 
 
10.
 
0 
 
DBP (mmHg) 75.
 
5 
 
± 6.
 
1 77.
 
0 
 
± 
 
16.
 
0 
 
76.
 
0
 
± 
 
4.
 
3 
 
75.
 
0 
 
± 
 
6.
 
0 
 
Cholesterol (mg/dl) 175.
 
0 
 
± 28.
 
0 180.
 
0 
 
± 
 
32.
 
0 
 
171.
 
0
 
± 
 
30.
 
0 
 
181.
 
0 
 
± 
 
34.
 
0 
 
Triglyceride (mg/dl) 149.
 
0 
 
± 91.
 
0 198.
 
0 
 
± 
 
66.
 
0 
 
158.
 
0
 
± 
 
81.
 
0 
 
193.
 
0 
 
± 
 
59.
 
0 
 
HDL (mg/dl) 41.
 
0 
 
± 12.
 
0 39.
 
0 
 
± 
 
7.
 
0 
 
38.
 
0
 
± 
 
12.
 
0 
 
35.
 
0 
 
± 
 
6.
 
0 
 
LDL (mg/dl) 109.
 
0 
 
± 26.
 
0 102.
 
0 
 
± 
 
22.
 
0 
 
102.
 
0
 
± 
 
26.
 
0 
 
107.
 
0 
 
± 
 
31.
 
0 
 
Legend: Data are mean ± SD. UAE: urinary albumin excretion. FPG: fasting plasma glucose. SBP: systolic blood pressure. DBP: diastolic blood 
pressure. HDL: high-density lipoprotein. LDL: low-density lipoprotein. * p < 0.05. 
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